Sumitomo, Roivant close $3 billion deal, forming Sumitovant
Phil TaylorPhil Taylor
December 31, 2019
A new international biotech – Sumitovant Biopharma – has been created after Sumitomo Dainippon’s strategic alliance with Roivant Sciences came to fruition as 2019 drew to a close.
The $3 billion transaction announced earlier this year involves the transfer of five of the Roivant group companies formed by biotech entrepreneur Vivek Ramaswamy – Myovant, Urovant, Enzyvant, Altavant, and Spirovant – to the newly-formed company.
Sumitomo has taken an 11% stake in Roivant as part of the deal and also has an option on six more companies in the Roivant umbrella group, which could also be rolled into the new company between now and 2024.
Sumitovant will operate as a wholly-owned subsidiary of Sumitomo, and will be led by ex-Genentech executive Myrtle Potter, who has been operating chair of Roivant since July 2018.
Other members of the new biotech’s leadership team include chief medical officer Sam Azoulay, commercial chief Adele Gulfo and chief digital officer Dan Rothman, who are all making the switch from Roivant. The new company will have offices in London and New York.
The deal is viewed as a bolt-on pipeline deal for Sumitomo, which has fallen behind its peers of late in bringing new candidates through its R&D pipeline, adding new clinical-stage candidates for women’s health, urology, prostate cancer, and multiple rare diseases including cystic fibrosis.
The Japanese company needs new products to bring to market as it prepares for the loss of patent protection to Latuda (lurasidone), a $1.6 billion drug for schizophrenia and bipolar depression that is facing a generics hit in 2023, and after some late-stage pipeline failures including napabucasin in pancreatic cancer.
“We are thrilled to have Sumitovant as one of the core growth engines for Sumitomo Dainippon,” said Sumitomo’s chief executive Hiroshi Nomura, who added that it is a key part of the company’s plan to become a ‘global specialised player’ by 2033.
Sumitovant comes into being with several drugs in its late-stage pipeline that could be launched in the next five years, including relugolix for uterine fibroids, endometriosis and advanced prostate cancer, vibegron for overactive bladder, RVT-802 for ultra-rare disease congenital athymia and rodatristat ethyl for pulmonary arterial hypertension (PAH).
Recent ROIV News
- Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 • PR Newswire (US) • 03/26/2024 10:22:00 PM
- Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update • GlobeNewswire Inc. • 02/13/2024 12:00:00 PM
- Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 • GlobeNewswire Inc. • 01/30/2024 09:05:00 PM
- Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease • GlobeNewswire Inc. • 12/20/2023 09:30:00 PM
- Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease • GlobeNewswire Inc. • 12/14/2023 02:00:00 PM
- Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential • GlobeNewswire Inc. • 11/28/2023 12:00:00 PM
- Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus • GlobeNewswire Inc. • 11/27/2023 01:00:00 PM
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update • GlobeNewswire Inc. • 11/13/2023 12:00:00 PM
- Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors • GlobeNewswire Inc. • 11/10/2023 01:00:00 PM
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 • GlobeNewswire Inc. • 10/30/2023 09:30:00 PM
- Trending: Roche to Buy Telavant From Roivant and Pfizer • Dow Jones News • 10/23/2023 07:41:00 PM
- Monday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and more • IH Market News • 10/23/2023 11:18:51 AM
- Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- Update • Dow Jones News • 10/23/2023 08:16:00 AM
- Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal • Dow Jones News • 10/23/2023 05:50:00 AM
- Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant • GlobeNewswire Inc. • 10/23/2023 05:00:00 AM
- Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer • GlobeNewswire Inc. • 10/13/2023 12:00:00 PM
- Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results • GlobeNewswire Inc. • 09/26/2023 10:00:00 AM
- Roivant Announces Completion of Redemption of its Outstanding Warrants • GlobeNewswire Inc. • 09/11/2023 12:00:00 PM
- Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants • GlobeNewswire Inc. • 08/17/2023 08:05:00 PM
- Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 11:00:00 AM
- Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023 • GlobeNewswire Inc. • 08/03/2023 08:05:00 PM
- Roivant Announces Redemption of Outstanding Warrants • GlobeNewswire Inc. • 08/02/2023 08:05:00 PM
- Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease • GlobeNewswire Inc. • 07/27/2023 12:00:00 PM
- Friday’s Wall Street Highlights: JPMorgan Chase, Coinbase, UPS, Theseus Pharmaceuticals, and more • IH Market News • 07/14/2023 11:51:14 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM